Use is restricted to:
• Patients with active relapsing–remitting multiple sclerosis previously treated with disease-modifying therapy, or rapidly evolving severe relapsing–remitting multiple sclerosis (that is, at least 2 relapses in the previous year and at least 1 gadolinium-enhancing lesion at baseline MRI) and
• Alemtuzumab is contraindicated or otherwise unsuitable and
• The company provides the drug with the discount agreed in the patient access scheme.